Anatoly K. Golenkov is a member of the Russian Academy of Natural Sciences, Professor, Doctor of Medical Science. Dr. Golenkov is the Head of the Clinical Hematology and Immunology Department at the M.V. Vladimirsky Moscow Regional Research Clinical Institute.
Dr. Golenkov studies pathogenesis of lymphoproliferative disorders (chronic lymphocytic leukemia, leukemias, multiple myeloma, Waldenström’s macroglobulinemia) and develops new methods of treatment.
Dr. Golenkov has more than 170 scientific articles in Russian and international publications, has written a monograph Multiple Myeloma (1995) and holds four patents.
Dr. Golenkov is a member of editorial boards of Hematology and Transfusiology and Russian Biotherapeutic Journal, academic board of the Hematological Center of RAMS, section on hematology and transfusiology of the Ministry of Health of Russia Academic Board. Dr. Golenkov is the Chief Hematologist of the Moscow Region and a member of the European Hematology Association.
Dr. Golenkov’s Clinical Hematology and Immunology Department was separated from the 1st Therapy Department and functions independently since January, 1990.
Scientific research at the department is dedicated to various aspects of lymphoproliferative disorders (multiple myeloma, macroglobulinemia, malignant lymphomas, chronic lymphocytic leukemia). A special priority of the department is in vitro research on blood and marrow tumor cell resistance to cytostatic compounds in 4-day cultures. This is a new approach to treatment of hematological malignancies and its development only recently started in Russia. Development of a deterministic approach to chemotherapy drugs prescription will allow doctors to receive full information on treatment efficiency and predict clinical response.
A new method of drug resistance overcoming in patients with lymphoproliferative disorders based on extracorporeal photomodification of peripheral lymphocytes is being developed at the department. This new method is a promising line of research as it potentially allows to modulate multiple drug resistance.
In recent years 1 Doctor of Medical Science dissertation and 6 PhD dissertations were defended at Dr. Golikov’s department. Since 1996 research conducted at the department has been supported by the Ministry of Science grants. The department has a wide network of international collaborations. For 5 years the department conducts scientific multicenter phase II and III trials of commercial medications.
The department treats 1,000 patients annually, mainly patients with oncohematological diseases. Doctors at the department use advanced chemotherapy programs which allow to achieve the same clinical effect (number and time of remission, quality of life) as in leading clinics worldwide.
